Index of artpub/2016/pmc_26802160/

Chiorean, E. G
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab -paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer
2016
https://ddd.uab.cat/record/185774